Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?

@article{Matthys2014ReviewOG,
  title={Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?},
  author={Frederik Matthys and Tine L M de Backer and Guy G. De Backer and Robert Vander Stichele},
  journal={European Journal of Preventive Cardiology},
  year={2014},
  volume={21},
  pages={354 - 365}
}
Aims There are numerous national and international guidelines on the use of aspirin for the primary prevention of cardiovascular disease. Given the uncertainties about aspirin in primary prevention, our aim was to compare the recommendations and the reported evidence in guidelines for the treatment with aspirin of subjects free of cardiovascular disease with or without diabetes. Methods and Results Guidelines were retrieved through Medline and other electronic databases and through a web-based… 

Figures from this paper

Low-dose aspirin for primary and secondary prevention of cardiovascular events in Denmark 1998–2018
TLDR
The widespread use of aspirin, especially among older adults, and substantial concomitant use of medications adding to bleeding risk warrant increased focus on discontinuation of inappropriate aspirin use.
Aspirin Use and Mortality in Two Contemporary US Cohorts
TLDR
Results from these 2 large population-based US cohorts confirm the utility of daily aspirin use for secondary prevention of cardiovascular mortality; however, the data suggest that caution should be exercised in more frequent use, particularly among individuals without a history of cardiovascular disease.
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of HypertensionWorking Group on Hypertension and Cardiovascular Risk in Low Resource Settings HYPERTENSION IN A GLOBAL PERSPECTIVE
TLDR
Current evidence for cardiovascular risk assessment in population studies in low-income and middle-income countries, their limitations, possible improvements, and future interests in screening programs are summarized and highlights of unmet needs are presented.
Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings
TLDR
Current evidence for cardiovascular risk assessment in population studies in low-income and middle-income countries, their limitations, possible improvements, and future interests in screening programs are summarized and highlights of unmet needs are presented.
Frequency of Aspirin Misuse Among Hypertensive Patients in Babylon Province
TLDR
Aspirin use requires coordinated interaction between patient and physician with encouraging the importance patient education about aspirin use, side effects and CVD risk and proper evaluation of patients risk factors and stratification using simplified charts accessible in health centers.
Pooled RCTs: Low-dose ASA reduced CV events in persons <70 kg; higher-dose ASA was effective at higher body weights
TLDR
In primary prevention, low- dose aspirin vs control reduced cardiovascular events in patients weighing <70 kg but not those weighing 70 kg, and higher-dose aspirin was effective at higher body weights.
Clinicians’ opinions on recommending aspirin to prevent colorectal cancer to Australians aged 50–70 years: a qualitative study
TLDR
Widespread adoption of these new guidelines could be an important strategy to reduce the incidence of bowel cancer, but this will require more active implementation strategies focused on primary care and the wider community.
Association between Aspirin Therapy and Clinical Outcomes in Patients with Non-Obstructive Coronary Artery Disease: A Cohort Study
Background Presence of non-obstructive coronary artery disease (CAD) is associated with increased prescription of cardiovascular preventive medications including aspirin. However, the association
A Geripill for Successful Aging
  • T. Strandberg
  • Medicine
    Journal of the American Geriatrics Society
  • 2013
TLDR
My reasons for shunning the aspirin, beta-blocker, and hydrochlorothiazide of the original “polypill” are the side effects and low evidence of benefit of aspirin in primary prevention and the good tolerability and benefits of newer antihypertensive drug combinations.
Reduction of intracerebral hemorrhage in hemodialysis patients after reducing aspirin use: A quality-assurance observational study
TLDR
Minimizing aspirin use in hemodialysis patients with severe hypertension reduced intracerebral bleeding without a significant difference in cardiovascular mortality.
...
...

References

SHOWING 1-10 OF 89 REFERENCES
Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale
TLDR
The USPSTF concluded that the balance of benefits and harms is most favorable in patients at high risk for coronary heart disease (those with a 5-year risk 3%) but is also influenced by patient preferences, and some persons at lower risk may consider the potential benefits of aspirin to outweigh the potential harms.
Aspirin for primary prevention: yes or no?
TLDR
Benefits of aspirin monotherapy outweigh the harms for both men and women aged up to 80 years with calculated five-year CVD risk >15% in primary prevention, and modelling by risk category and age group suggests that current guidelines are justified in recommending aspirin for primary prevention of CVD.
Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis
TLDR
The use of aspirin cannot be routinely recommended for primary prevention of cardiovascular events in diabetes, as existing trials were limited by small patient numbers and low cardiovascular event rates.
An update on aspirin in the primary prevention of cardiovascular disease.
TLDR
The current totality of evidence provides strong support for the initial finding that aspirin reduces the risk of a first MI, and the benefits of long-term aspirin therapy are likely to outweigh any risks.
Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies.
TLDR
Aspirin was associated with UGIC even when used at low doses or in buffered or enteric-coated formulations, and the latter findings may be partially explained by channeling of susceptible patients to these formulations.
...
...